[1] Böttcher K, Rombouts K, Saffioti F, et al. MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation. Hepatology, 2018, 68(1): 172-186.
[2] 郭银燕, 钟艳丹, 俞海英, 等. 自身免疫性肝病的临床和病理特征分析. 安徽医药, 2023, 27(5): 976-980.
[3] Mack C L, Adams D, Assis D N, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology, 2020, 72(2): 671-722.
[4] 郑林华, 尚玉龙, 韩者艺, 等. 急性重症自身免疫性肝炎的临床特征和预后分析. 中华肝脏病杂志, 2022, 30(1): 69-73.
[5] Hao L R, Li X F, Gao C, et al. Th17/Treg cell level and clinical characteristics of peripheral blood of patients with Sjogren's syndrome complicated with primary biliary cirrhosis. Medicine, 2019, 98(24): 15952.
[6] Sarcognato S, Sacchi D, Grillo F, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica, 2021, 113(3): 170-184.
[7] Teruel M, Barturen G, Martínez-Bueno M, et al. Integrative epigenomics in Sjgren' s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. Sci Rep, 2021, 11(1): 23292.
[8] 魏风芹, 杨晟楠, 刘培培, 等. 原发性干燥综合征合并间质性肺疾病的生物标志物进展. 国际呼吸杂志, 2021, 41(21): 1610-1615.
[9] 王绮夏, 蒋翔, 连敏, 等. 2015年欧洲肝病学会临床实践指南:自身免疫性肝炎. 临床肝胆病杂志, 2015, 31(12): 2000-2019.
[10] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015). 临床肝胆病杂志, 2015, 31(12): 1980-1988.
[11] 中华医学会风湿病学分会. 干燥综合征诊治指南(草案). 中华风湿病学杂志, 2003, 7(7): 446-448.
[12] Kolev M, Sarbu A C, WAILDer A, et al. Belimumab in autoimmune liver diseases with associated Sjögren’s syndrome. Swiss Med Weekly, 2021, 151(253): 25.
[13] Gaber Y, AbdAllah M, Salama A, et al. Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. Expert Rev Gastroenterol Hepatol, 2021, 15(10): 1181-1189.
[14] 陈伟钱, 戴小娜, 余叶, 等. 原发性干燥综合征合并自身免疫性肝病的临床特点及预后分析. 北京大学学报(医学版), 2020, 52(5): 886-891.
[15] De V E, Bolier R, Goet J, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology, 2021, 160(3): 734-743.
[16] Perez C F M, Harms M H, Lindor K D, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol, 2020, 115(7): 1066-1074.
[17] Verstappen G M, Moerman R V, van Nimwegen J F, et al. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren’s syndrome. Rheumatology, 2018, 57(10): 1812-1821.
[18] Ning Y, Ke-Shuai S U N, Si-Yuan T, et al. Clinical characteristics analysis of primary biliary cholangitis with features of autoimmune hepatitis. Med J Chin PLA, 2021, 46(1): 36-41.
[19] Wu H M, Sheng L, Wang Q, et al. Performance of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome. World J Gastroenterol, 2018, 24(6): 737.
[20] 朱林林, 杨李桦, 谢其冰, 等. 自身免疫性肝炎合并干燥综合征的临床病理特点分析. 四川大学学报(医学版), 2018, 49(2): 183-187. |